30 April 2026, Philadelphia: FMC Corporation reported first quarter 2026 revenue of $759 million, representing a 4 percent decline compared to the same period last year.

Revenue excluding India stood at $762 million, also down 4 percent year-on-year.

On a GAAP basis, the company reported a loss of $2.25 per diluted share, a decrease of $2.13 compared to Q1 2025. Adjusted loss per diluted share was $0.23, down 41 cents year-on-year.

• Revenue of $759 million, down 4 percent versus Q1 2025
• Revenue excluding India of $762 million, down 4 percent versus Q1 2025
• Organic revenue declined 9 percent
• Consolidated GAAP net loss of $281 million, a decline of $266 million versus Q1 2025
• Adjusted EBITDA of $72 million, down 40 percent versus Q1 2025
• GAAP loss of $2.25 per diluted share, down $2.13 versus Q1 2025
• Adjusted loss per diluted share of $0.23, down 41 cents versus Q1 2025

FMC Revenue

Sales excluding India reached $762 million, coming in above the midpoint of guidance but still 4 percent lower than the previous year. The removal of India contributed a 5 percent headwind.

Price declined 6 percent due to lower pricing to diamide partners, pricing adjustments on branded Rynaxypyr® products, and competitive pressure in legacy core products, particularly in Latin America.

Foreign exchange provided a 5 percent tailwind, while volume increased 2 percent driven by strong growth in EMEA and North America. Sales of new active ingredients doubled year-on-year, and Plant Health grew by 6 percent.

FMC Regional Revenue ($M)

Growth in EMEA and North America offset declines in Latin America and Asia.

GAAP net loss increased primarily due to tax charges related to higher valuation allowances. Additional pressures included lower sales, higher restructuring costs, and increased interest expense.

Adjusted EBITDA declined 40 percent to $72 million, driven by lower pricing and unfavorable costs, including tariffs and higher raw material expenses.

Cash from operations was negative $601 million, down $56 million versus the prior year, largely due to lower EBITDA. Free cash flow stood at negative $628 million, a decline of $32 million, partially offset by reduced capital expenditures.

FMC continues to execute its 2026 operational priorities, including:

• Targeted debt reduction of approximately $1 billion
• Enhancing competitiveness of its core portfolio
• Managing the post-patent transition of Rynaxypyr® active
• Driving growth in new active ingredients such as Isoflex®, fluindapyr, and Dodhylex®

The company is also progressing with its evaluation of strategic alternatives announced in February 2026, with multiple options under consideration.

The company reaffirmed its full-year guidance:

• Revenue (excluding India): $3.60 billion to $3.80 billion (down 5 percent at midpoint)
• Adjusted EBITDA: $670 million to $730 million (down 17 percent)
• Adjusted EPS: $1.63 to $1.89 (down 41 percent)
• Free cash flow: negative $65 million to $65 million